Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract

• Status: Unknown status
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chakshu Research, Inc.
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Presence of nuclear sclerosis cataract

• BCDVA within the range of 20/40 and 20/80

Exclusion Criteria:

• Any other clinical condition in the eye that may compromise vision

• Presence or history of glaucoma

• Presence or history of diabetes

• Use of eyedrops

• Use of steroids